MSB_logo_notag (001).jpg
First Allogeneic Cell Therapy Product Launched in Japan by Mesoblast Licensee
February 24, 2016 06:00 ET | Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) announced that its licensee in Japan, JCR Pharmaceuticals Co. Ltd., today launched...
MSB_logo_notag (001).jpg
Mesoblast’s Cell Therapy Increases Survival in Children With Acute Graft Versus Host Disease
February 22, 2016 05:00 ET | Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB;) today announced that results have been presented showing that use of its proprietary...
MSB_logo_notag (001).jpg
Mesoblast Reports on First Half and Second Quarter Financial Results
February 16, 2016 16:40 ET | Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today reported financial results and operational highlights for the 1H/2Q ended 31...
MSB_logo_notag (001).jpg
Mesoblast Cell Therapy Shows Clinical Benefit in First Cohort of Patients With Biologic Refractory Rheumatoid Arthritis
February 16, 2016 06:00 ET | Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced results from the first cohort of its ongoing Phase 2 trial in...
MSB_logo_notag (001).jpg
Mesoblast to Host Second Quarter and First Half Financial Results Conference Call and Webcast
February 11, 2016 11:00 ET | Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the second quarter/half year...
MSB_logo_notag (001).jpg
Phase 3 Heart Failure Trial Size to be Substantially Reduced Following FDA Discussions
January 11, 2016 08:00 ET | Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that the size of the ongoing Phase 3 trial in chronic heart failure...
MSB_logo_notag (001).jpg
Mesoblast to Present at the 34th Annual J. P. Morgan Healthcare Conference
January 07, 2016 17:56 ET | Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that it will present at the 34th Annual J. P. Morgan Healthcare...
MSB_logo_notag (001).jpg
Mesoblast Provides Strategic Update and Reports on First Quarter Financial Results
December 16, 2015 16:57 ET | Mesoblast Limited
Materially Strengthened Cash Reserves First Royalties From TEMCELL Product Sales Expected In Q1 2016 Resources Prioritized On Tier 1 Product Candidates Cash Managed To Extend Runway And Achieve...
MSB_logo_notag (001).jpg
Mesoblast to Host First Quarter Financial Results Conference Call and Webcast on 16 December 2015
December 15, 2015 19:50 ET | Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced it will report financial results for the quarter ended 30 September...
MSB_logo_notag (001).jpg
Mesoblast’s Japan Licensee Receives Pricing for TEMCELL® HS Inj. for Treatment of Acute Graft Versus Host Disease
November 27, 2015 06:00 ET | Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Nov. 27, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that its licensee in Japan, JCR Pharmaceuticals Co. Ltd., has received...